Literature DB >> 32259322

Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records.

Shouhua Yang1, Yuan Zhang1, Jing Cai1, Zehua Wang1.   

Abstract

From a large medical center in Wuhan, the epicenter of the 2019 novel coronavirus disease (COVID-19), we report clinical features and prognosis for three women diagnosed with COVID-19 after gynecologic oncology surgery and hospitalized in January 2020. The incidence of COVID-19 was 0.77% (3 of 389) of total hospitalizations and 1.59% (3 of 189) of patients undergoing surgeries in the ward. The infection of severe acute respiratory syndrome coronavirus 2 may be related to the older age, comorbidities, malignant tumor, and surgery in gynecologic hospitalizations. By February 20, 2020, only two of the three patients had met the clinical discharge criteria. Given the long and uncertain incubation period of COVID-19, screening for the virus infection should be carried out for all patients, both preoperatively and postoperatively. Postponement of scheduled gynecologic surgery for patients in the epidemic area should be considered. © AlphaMed Press 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32259322      PMCID: PMC7262154          DOI: 10.1634/theoncologist.2020-0157

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


Introduction

China and the rest of the world are experiencing an outbreak of the 2019 novel coronavirus disease (COVID‐19). By February 22, 2020, the rapid spread of the virus had caused 77,041 infections and 2,445 deaths in China, and emerging cases have been reported in more than 30 countries, including the U.S., Japan, and South Korea. More than two thirds of cases and deaths from the infection occurred in Wuhan, China. On January 31, 2020, the World Health Organization declared COVID‐19, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a public health emergency of international concern. Patients with cancer are more susceptible to viral infection than healthy individuals because of their systemic immunosuppressive status caused by the malignancy and anticancer treatments, such as surgery or chemotherapy; therefore, these patients might be at increased risk for COVID‐19 and have a poorer prognosis 1. As one of the largest medical centers in Wuhan, ground zero of the outbreak, our hospital encountered patients with COVID‐19 with various medical conditions. Here, we report the results of a retrospective review of medical records from three women diagnosed with COVID‐19 after gynecologic surgery in our Gynecologic Oncology ward in January 2020; each had met the diagnostic criteria of the New Coronavirus Pneumonia Prevention and Control Program (6th edition), published by the National Health Commission of China 2.

Results

From January 1, 2020, to January 31, 2020, three women were postoperatively diagnosed with COVID‐19 in our Gynecologic Oncology ward (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology). The incidence of COVID‐19 was 0.77% (3 of 389) of the total hospitalizations and 1.59% (3 of 189) among the patients undergoing surgeries in the ward and hospitalized during the same time period. There were no COVID‐19 diagnoses in the 200 patients without surgery. Among the 189 patients with gynecologic tumors who had received surgery, COVID‐19 occurred predominantly in those with malignant diseases, with comorbidities (hypertension, diabetes, and cardiovascular disease), aged >45 years, and with postoperative fever persisting for 3 days or longer (Table 1).
Table 1

The incidence of COVID‐19 in different subgroups of patients hospitalized after gynecologic oncology surgery

n COVID‐19, n (%) p valuea
Tumor type
Malignant332 (6.1).0236
Benign1561 (0.6)
Comorbiditiesb
Yes403 (7.5).0075
No1490
Age, year
>45693 (4.3).0213
≤451200
Fever ≥3 days
Yes93 (33.3)<.0001
No1800

Fisher's exact test.

Hypertension, diabetes, and cardiovascular disease.

The incidence of COVID‐19 in different subgroups of patients hospitalized after gynecologic oncology surgery Fisher's exact test. Hypertension, diabetes, and cardiovascular disease. The detailed clinical features and disease courses of the three COVID‐19 cases are summarized in Table 2. The three patients did not report any direct contact with infected individuals, and their x‐rays and computed tomography (CT) scans of the chest did not show any abnormality preoperatively. The patients developed fever within 2 days after surgery, which persisted (highest temperatures of 38.7°C–39.4°C) despite the administration of anti‐inflammatory drugs (cephalosporin, meropenem, and moxifloxacin). One patient had a cough and significantly decreased blood oxygen. Positive CT findings showed signs of a viral pneumonia approximately 10 days after surgery in all three patients (Fig. 1), whereas two of them had a negative chest x‐ray or CT on days 4–6 postoperatively. All patients had negative results from tests of blood and throat swab samples for seven common respiratory pathogens, including respiratory syncytial virus, adenovirus, mycoplasma pneumoniae, chlamydia pneumoniae, coxsackievirus group B, the influenza B virus, and the influenza A virus. Finally, the viral DNA of SARS‐CoV‐2 was detected in the throat swab samples from the patients by using assays based on the real‐time reverse transcriptase polymerase chain reaction technique.
Table 2

Clinical features of the three women diagnosed with COVID‐19 after gynecological oncology surgery

FeatureCase 1Case 2Case 3
Age, years474859
ResidenceWuhanHuanggang (90 km from Wuhan)Zhumadian (260 km from Wuhan)
ComorbiditiesDiabetes and hypertensionDiabetes and hypertensionHypertension
Known contact historya NoNoNo
Preoperative chest imagingb X‐ray (−)X‐ray (−), CT (−)X‐ray (−)
Gynecologic conditionEndometrial atypical hyperplasiaSquamous cervical cancer, stage I B1Epithelial ovarian cancer, stage III C
SurgeryHysterectomyRadical hysterectomyCytoreductive surgery
Timing of fever onset (days after hospitalization)5 days9 days5 days
Timing of fever onset (days after surgery)1 day2 days1 days
Fever peak39.4°C38.8°C38.7°C
CoughYesNoNo
Shortness of breath or fatigueNoNoNo
Lowest SpO290%97%98%
Postoperative chest imaging, days after surgeryb X‐ray (−), 6 days; CT (+), 9 daysCT (+), 10 daysCT (−), 4 days; CT (+), 10 days
White blood cells6.57 g/L3.96 g/L2.97 g/L
Lymphocytes0.53 g/L0.85 g/L0.67 g/L
CRP37.50 mg/L36.36 mg/L9.44 mg/L
ESR81 mm/h57 mm/hNA
D‐dimer1.16 ng/mL9.41 ng/mL12.49 ng/mL
Procalcitonin<0.13 μg/L<0.13 μg/L0.28 μg/L
SARS‐CoV‐2PositivePositivePositive
Blood culture for bacteriaNegativeNegativeNegative
AST38 U/L192 U/Lc 27 U/L
ALT29 U/L106 U/Lc 20 U/L
Prognosis by Feb. 20DischargedDischargedIn hospital

History of direct contact with other individuals infected with SARS‐CoV‐2.

(−), no signs of a viral pneumonia; (+), images of viral pneumonia.

This patient had undergone chemotherapy for three cycles before surgery. The elevated AST and ALT may be caused by the drugs.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C‐reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; NA, Not applicable; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; SpO2, peripheral oxygen saturation.

Figure 1

Representative chest computed tomography images of COVID‐19 in three women after gynecologic surgery: multiple regions of patchy consolidation and ground‐glass opacities in bilateral lungs, coupled with scattered lesions along the bronchial bundles or the subpleural lungs.

Clinical features of the three women diagnosed with COVID‐19 after gynecological oncology surgery History of direct contact with other individuals infected with SARS‐CoV‐2. (−), no signs of a viral pneumonia; (+), images of viral pneumonia. This patient had undergone chemotherapy for three cycles before surgery. The elevated AST and ALT may be caused by the drugs. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C‐reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; NA, Not applicable; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; SpO2, peripheral oxygen saturation. Representative chest computed tomography images of COVID‐19 in three women after gynecologic surgery: multiple regions of patchy consolidation and ground‐glass opacities in bilateral lungs, coupled with scattered lesions along the bronchial bundles or the subpleural lungs. The patients were transferred to a quarantine hospital and treated with antiviral drugs (oseltamivir or umifenovir) combined with supportive care. As of February 20, 2020, two of the three patients had been discharged from the hospital because they had met the discharge criteria (i.e., they had neither fever nor cough for at least 3 days, the lesions of lung had become much smaller according to chest CT imaging, and repeated negative results had been obtained in at least two consecutive viral DNA tests on different days 2); at this writing, the third patient was still being treated at the quarantine hospital.

Discussion

In previous studies, nearly half of patients with COVID‐19 had underlying chronic diseases, such as diabetes, hypertension, and cardiovascular disease, and the common symptoms at onset of illness included fever, cough, shortness of breath, and fatigue. Most patients had lymphopenia, and nearly all patients had pneumonia with abnormal findings on chest CT. Some patients developed acute respiratory distress syndrome, and some of these patients worsened in a short period of time and died of multiple organ failure 3, 4. Generally, the incubation period for COVID‐19 can last 2 weeks, or longer 2, 5 considering that CT scan rather than x‐ray of the chest plays an essential role in the diagnosis of COVID‐19 and that the viral detection assays are not always available or accurate 6. In the epidemic area, it would be helpful to use CT scans to screen patients preoperatively. For patients with persisting fever after surgery, a lung CT scan needs to be done in a timely manner. Data suggest that men are more susceptible than women, but in fact all populations are susceptible, including women 2, 3. Some studies reported that, with the rapid spread of the disease, many COVID‐19 diagnoses were made in people who had not had direct contact with other individuals infected with SARS‐CoV‐19 7. In the current study, only one of three affected persons was from metropolitan Wuhan, and the others were from nearby. In an epidemic area of COVID‐19, more intensive surveillance for SARS‐CoV‐2 should be done before surgery. After surgery, if a patient's fever lasts for more than 3 days or is accompanied by respiratory symptoms, then COVID‐19 testing should be performed, even if the patient has had no contact with other verified cases. In the present case report, the patients were older than the average age of the patients in the ward during the same time period, suggesting that age also may be a risk factor for COVID‐19 after gynecologic tumor surgery. It was also observed, in all three cases, that the white blood cell count was not high and the lymphocyte count was reduced. One important finding was that there were no COVID‐19 diagnoses in the no‐surgery group, including 200 hospitalizations. It is suggested that only emergency gynecologic operations should be scheduled in an epidemic area.

Conclusion

We found that patients undergoing gynecological surgery were at risk for clinical manifestations of COVID‐19 after surgery in a gynecologic oncology ward. Postponement of scheduled gynecologic surgery for patients in the epidemic area is important and should be considered. More intensive surveillance for SARS‐CoV‐2 should be considered for patients undergoing gynecologic surgery, especially for patients with fever for more than 3 days, older patients, and patients with comorbidities.

Disclosures

The authors indicated no financial relationships.
  6 in total

1.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

2.  Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China.

Authors:  Heshui Shi; Xiaoyu Han; Chuansheng Zheng
Journal:  Radiology       Date:  2020-02-07       Impact factor: 11.105

3.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

4.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

5.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

6.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Authors:  Wenhua Liang; Weijie Guan; Ruchong Chen; Wei Wang; Jianfu Li; Ke Xu; Caichen Li; Qing Ai; Weixiang Lu; Hengrui Liang; Shiyue Li; Jianxing He
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316

  6 in total
  12 in total

1.  Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.

Authors:  Ali Ayhan; Murat Oz; Nazli Topfedaisi Ozkan; Koray Aslan; Müfide Iclal Altintas; Hüseyin Akilli; Erdal Demirtas; Osman Celik; Mustafa Mahir Ülgü; Suayip Birinci; Mehmet Mutlu Meydanli
Journal:  Gynecol Oncol       Date:  2020-11-17       Impact factor: 5.482

2.  Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis.

Authors:  P Zarifkar; A Kamath; C Robinson; N Morgulchik; S F H Shah; T K M Cheng; C Dominic; A O Fehintola; G Bhalla; T Ahillan; L Mourgue d'Algue; J Lee; A Pareek; M Carey; D J Hughes; M Miller; V K Woodcock; M Shrotri
Journal:  Clin Oncol (R Coll Radiol)       Date:  2020-11-19       Impact factor: 4.126

Review 3.  Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China.

Authors:  Zhilan Chen; Chun Zhang; Jiu Yin; Xin Xin; Hemei Li; Yapei Wang; Benjamin K Tsang; Qinghua Zhang
Journal:  J Ovarian Res       Date:  2021-02-18       Impact factor: 4.234

4.  Care as Usual: An Acceptable Strategy to Apply During the COVID-19 Pandemic in a French Tertiary Gynecologic Oncology Department.

Authors:  Guillaume Blache; Houssein El Hajj; Camille Jauffret; Gilles Houvenaeghel; Laura Sabiani; Julien Barrou; Isabelle Masquin; Jérémy Le Saout; Djamel Mokart; Marion Faucher; Eric Lambaudie
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

5.  Practical Recommendations for the Preoperative Screening and Protective Protocols in Cancer Surgeries During COVID-19: A Systematic Review.

Authors:  Sara Dorri; Fateme Sari; Seyedeh Nahid Seyedhasani; Alireza Atashi; Esmatalsadat Hashemi; Asiie Olfatbakhsh
Journal:  Front Surg       Date:  2021-11-23

6.  System Analysis of Adaptor-Related Protein Complex 1 Subunit Mu 2 (AP1M2) on Malignant Tumors: A Pan-Cancer Analysis.

Authors:  Yuanxue Yi; Qiufang Zhang; Youfeng Shen; Yueyi Gao; Xiaohong Fan; Sini Chen; Xin Ye; Jian Xu
Journal:  J Oncol       Date:  2022-02-10       Impact factor: 4.375

7.  Reengineering academic departments of obstetrics and gynecology to operate in a pandemic world and beyond: a joint American Gynecological and Obstetrical Society and Council of University Chairs of Obstetrics and Gynecology statement.

Authors:  Ronald D Alvarez; Barbara A Goff; David Chelmow; Todd R Griffin; Errol R Norwitz; John O De Lancey
Journal:  Am J Obstet Gynecol       Date:  2020-06-17       Impact factor: 8.661

8.  Results of the Survey Conducted Among Caribbean Physicians on a Zoom Meeting Discussing the Article "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group".

Authors:  Nandan Maruti Shanbhag; Albert Duncan; Elizabet Gomes Dos Santos; Hanybal Yazigi; Merisa Grant-Tate; Nevein Farouk Francis Girgis; Niurka B MoyaSantos; Vincent Vinh-Hung; Yanelis Leon Duran
Journal:  Oncologist       Date:  2020-10-29       Impact factor: 5.837

9.  Systematic Analysis of Coronavirus Disease 2019 (COVID-19) Receptor ACE2 in Malignant Tumors: Pan-Cancer Analysis.

Authors:  Jukun Song; Jing Han; Feng Liu; Xianlin Chen; Shenqi Qian; Yadong Wang; Zhenyu Jia; Xiaofeng Duan; Xiangyan Zhang; Jianguo Zhu
Journal:  Front Mol Biosci       Date:  2020-10-23

10.  Impact of cancer on mortality and severity of corona virus disease 2019: A protocol for systematic review and meta-analysis.

Authors:  Yi Zhang; Hao Han; Yunling Tian; Jing Dong; Yage Yu; Yingying Kang; Lina Xing; Rongna Lian; Ruinian Zhang; Dairong Xie
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.